Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PSR001
MIFTS: 65

Psoriatic Arthritis

Categories: Genetic diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Psoriatic Arthritis

About this section

MalaCards integrated aliases for Psoriatic Arthritis:

Name: Psoriatic Arthritis 57 12 76 25 75 43 15
Psoriatic Arthritis, Susceptibility to 57 29 13 6
Psoriatic Arthropathy 12 25 75
Arthropathic Psoriasis 12 25
Arthritis, Psoriatic 44 73
Arthritis, Psoriatic, Susceptibility to 40
Psoriasis Arthropathica 75
Arthritis Psoriatica 12
Arthritic Psoriasis 75
Arthritis Psoriatic 55
Psoras 75

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 607507
Disease Ontology 12 DOID:9008
ICD10 33 L40.5 L40.50
ICD9CM 35 696.0
MeSH 44 D015535
NCIt 50 C61277
UMLS 73 C0003872
Sources

Summaries for Psoriatic Arthritis

About this section
MedlinePlus : 43 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.

MalaCards based summary : Psoriatic Arthritis, also known as psoriatic arthritis, susceptibility to, is related to spondyloarthropathy 1 and arthritis, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Adalimumab and Certolizumab pegol have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A syndrome that occurs in humans with psoriasis who also experience symptoms similar to arthritis.

Genetics Home Reference : 25 Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.

OMIM : 57 Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong but complex genetic basis, with a concordance rate of 50 to 70% among monozygotic twins. Psoriatic arthritis affects more than 10% of patients with psoriasis and, in most cases, there is an association between the severity of the arthritis and the skin involvement (Gudjonsson et al., 2002). (607507)

UniProtKB/Swiss-Prot : 75 Psoriatic arthritis: An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

Wikipedia : 76 Arthritis is a term often used to mean any disorder that affects joints.Symptoms generally include joint... more...

Sources

Related Diseases for Psoriatic Arthritis

About this section

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 309)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 33.3 CRP HLA-B MMP3 NOD2 TNF TNFRSF11B
2 arthritis 32.6 IL1B LTA MICA MMP3 PTPN22 TNF
3 osteoarthritis 31.2 COMP IL1B MMP3 TNF
4 spondyloarthropathy 31.2 HLA-B HLA-C MMP3 TNF TNFSF11
5 reactive arthritis 31.2 COMP CRP HLA-B TNF
6 cholangitis 31.1 CRP HLA-B TNF
7 spondylitis 31.1 CRP HLA-B HLA-C LTA MICA NOD2
8 psoriasis 31.1 HLA-C IL13 IL1B LTA MICA MIR146A
9 complex regional pain syndrome 31.0 HLA-B IL1B TNF
10 meningitis 31.0 CRP IL1B TNF
11 uveitis 30.9 HLA-B NOD2 TNF
12 tonsillitis 30.9 IL1B LTA TNF
13 sclerosing cholangitis 30.9 HLA-B HLA-C TNF
14 adult-onset still's disease 30.9 CRP IL1B TNF
15 spondylarthropathy 30.9 LTA TNF
16 vasculitis 30.9 CRP SELE TNF TNFRSF1B
17 crohn's disease 30.9 CRP IL1B NOD2 TNF TNFRSF1B
18 lyme disease 30.9 CRP IL1B TNF
19 juvenile rheumatoid arthritis 30.8 CRP IL1B LTA TNF TNFRSF1B
20 pneumonia 30.8 CRP IL13 IL1B TNF
21 skin disease 30.8 HLA-B HLA-C IL13 SELE TNF
22 rheumatic disease 30.7 CRP HLA-B IL1B TNF TNFRSF11B
23 leishmaniasis 30.7 IL13 IL1B TNF
24 ulcerative colitis 30.7 CRP IL1B NOD2 TNF
25 joint disorders 30.6 IL1B MMP3 TNF TNFSF11
26 arteries, anomalies of 30.6 CRP IL1B SELE TNF
27 visceral leishmaniasis 30.6 CRP IL13 IL1B TNF
28 multicentric reticulohistiocytosis 30.6 TNFRSF11B TNFSF11
29 diabetes mellitus 30.4 CRP HLA-B IL1B LTA PTPN22 TNF
30 bone disease 30.3 IL1B TNF TNFRSF11B TNFSF11
31 osteoporosis 30.3 CRP IL1B MMP3 TNF TNFRSF11B TNFSF11
32 autoimmune disease 30.3 HLA-B IL1B PTPN22 TNF TNFRSF1B
33 systemic lupus erythematosus 30.1 CRP LTA PTPN22 SELE TNF TNFRSF1B
34 arthropathy 30.0 COMP CRP MICA TNF TNFRSF11B TNFSF11
35 aseptic meningitis 30.0 CD58 IL1B TNF
36 pericarditis 29.9 CRP IL1B TNF TNFRSF1A
37 periodontitis 29.9 CRP IL1B MMP3 TNF TNFRSF11B TNFSF11
38 periodontal disease 29.9 CRP IL1B MMP3 TNF TNFRSF11B TNFSF11
39 synovitis 29.7 COMP CRP IL1B MMP3 SELE TNF
40 familial mediterranean fever 29.6 CRP IL1B NOD2 TNF TNFRSF1A
41 rheumatoid arthritis 27.2 COMP CRP HLA-B IL1B MIR146A MMP3
42 psoriatic juvenile idiopathic arthritis 11.7
43 psoriasis 1 11.1 HLA-C MICA
44 sympathetic ophthalmia 11.1 HLA-C LTA TNF
45 alveolar echinococcosis 11.1 HLA-B HLA-C TNF
46 glaucomatocyclitic crisis 11.1 HLA-B HLA-C
47 hematopoietic stem cell transplantation 11.1 HLA-B HLA-C TNF
48 geographic tongue 11.1 HLA-B HLA-C TNF
49 inflammatory bowel disease 3 11.1 MICA NOD2 TNF
50 systemic onset juvenile idiopathic arthritis 11.0 IL1B TNF

Graphical network of the top 20 diseases related to Psoriatic Arthritis:



Diseases related to Psoriatic Arthritis
Sources

Symptoms & Phenotypes for Psoriatic Arthritis

About this section

Clinical features from OMIM:

607507

UMLS symptoms related to Psoriatic Arthritis:


back pain, muscle cramp, sciatica

GenomeRNAi Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

26 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.28 HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.28 MICA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.28 HLA-C HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.28 HLA-C HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.28 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.28 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.28 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.28 SELE
9 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.28 HLA-C HLA-B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.28 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.28 NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.28 NOD2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.28 HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.28 SELE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.28 HLA-B MICA NOD2 HLA-C SELE
16 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.28 NOD2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.28 NOD2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.28 HLA-C
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.28 NOD2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.28 HLA-B HLA-C
21 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.28 NOD2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.28 SELE
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.28 NOD2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.28 MICA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.28 HLA-C
26 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.28 MICA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.28 HLA-C HLA-B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.28 HLA-C HLA-B
29 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.28 MICA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.28 HLA-C
31 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 NOD2 IL1B TNF LTA TNFRSF1A TNFRSF1B
32 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 NOD2 IL1B TNF LTA TNFRSF11B TNFRSF1A

MGI Mouse Phenotypes related to Psoriatic Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 NOD2 IL13 PTPN22 IL1B SELE LTA
2 hematopoietic system MP:0005397 10.22 NOD2 IL13 PTPN22 IL1B SELE LTA
3 homeostasis/metabolism MP:0005376 10.21 MMP3 CRP NOD2 IL13 PTPN22 IL1B
4 cardiovascular system MP:0005385 10.2 CRP PTPN22 IL1B SELE LTA COMP
5 immune system MP:0005387 10.2 CRP NOD2 IL13 PTPN22 IL1B SELE
6 integument MP:0010771 9.86 IL13 IL1B SELE TNF TNFSF11 TNIP1
7 liver/biliary system MP:0005370 9.7 PTPN22 SELE LTA TNF TNIP1 TNFRSF1A
8 respiratory system MP:0005388 9.56 IL13 PTPN22 SELE LTA TNFSF11 TNFRSF1A
9 skeleton MP:0005390 9.36 NOD2 IL13 IL1B LTA COMP MMP3
Sources

Drugs & Therapeutics for Psoriatic Arthritis

About this section

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 3,Phase 2,Not Applicable 331731-18-1 16219006
2
Certolizumab pegol Approved Phase 4,Phase 3,Phase 1 428863-50-7
3
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 185243-69-0
4
Infliximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 170277-31-3
5
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
8
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 608141-41-9 11561674
9
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
11
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
12 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
13 Adrenocorticotropic Hormone Phase 4
14 beta-endorphin Phase 4
15 Hormone Antagonists Phase 4,Phase 2,Phase 1
16 Hormones Phase 4,Phase 2,Phase 1
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
18 Melanocyte-Stimulating Hormones Phase 4
19 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Vaccines Phase 4,Phase 3,Phase 2
37 Antifungal Agents Phase 4
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Calcineurin Inhibitors Phase 4
40 Cyclosporins Phase 4
41 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
42 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46
Tofacitinib Approved, Investigational Phase 3 477600-75-2
47
Ustekinumab Approved, Investigational Phase 3,Phase 2 815610-63-0
48
Azithromycin Approved Phase 3 83905-01-5 55185 447043
49
Doxycycline Approved, Investigational, Vet_approved Phase 3,Not Applicable 564-25-0 54671203
50
Rifampicin Approved Phase 3 13292-46-1 5458213 5381226

Interventional clinical trials:

(show top 50) (show all 319)
# Name Status NCT ID Phase Drugs
1 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
4 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
5 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis Completed NCT00245960 Phase 4 etanercept
6 HUmira in Psoriatic Arthritis Completed NCT01465438 Phase 4 Adalimumab
7 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) Completed NCT00127842 Phase 4 Etanercept
8 Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis Completed NCT00432406 Phase 4 Infliximab;Etanercept
9 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
10 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
11 Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
12 TNFalfa Blocking Treatment of Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
13 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4 Infliximab
14 Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence Completed NCT01079988 Phase 4 Cyclosporins;Retinoids;Systemic corticosteroids;Methotrexate;Systemic corticosteroids/methotrexate
15 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet Completed NCT00735787 Phase 4
16 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
17 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL) Recruiting NCT02814175 Phase 4 methotrexate (MTX)
18 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis Recruiting NCT03151551 Phase 4 Ixekizumab;Adalimumab
19 Vascular Inflammation in Psoriasis - Apremilast Recruiting NCT03082729 Phase 4 Apremilast
20 Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo Active, not recruiting NCT02798211 Phase 4 Secukinumab;Secukinumab
21 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
22 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
23 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) Not yet recruiting NCT03419650 Phase 4 ACTHar
24 Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis Not yet recruiting NCT03445845 Phase 4 Secukinumab;TNF blocker
25 Treatment With Apremilast in Patients With Psoriatic Arthritis Withdrawn NCT02558361 Phase 4 Treatment with Apremilast
26 Initial Treatment With Golimumab in Early PsA Unknown status NCT01871649 Phase 3 golimumab;methotrexate
27 Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis Completed NCT02024646 Phase 3 210 mg brodalumab;140 mg brodalumab;Placebo
28 TIght COntrol of Psoriatic Arthritis Completed NCT01106079 Phase 3 Intensive management or Tight control;Standard management - Control group
29 Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Completed NCT01925768 Phase 3 Apremilast 30 mg;Placebo
30 Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients Completed NCT02065713 Phase 3 Golimumab;Methotrexate;Placebo
31 Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Completed NCT01892436 Phase 3 Secukinumab
32 Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study Completed NCT01877668 Phase 3 Tofacitinib 5 mg BID;Tofacitinib 10 mg BID;Adalimumab;Placebo;Placebo
33 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors Completed NCT01882439 Phase 3 Tofacitinib;Tofacitinib;Tofacitinib;Tofacitinib
34 Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) Completed NCT00235885 Phase 3 adalimumab
35 Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Completed NCT01392326 Phase 3 Secukinumab (75 mg);Secukinumab (150 mg);Placebo Comparator
36 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01172938 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
37 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01212757 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
38 PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01212770 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo
39 Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Completed NCT02164214 Phase 3 etanercept Treatment
40 Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis Completed NCT00195689 Phase 3
41 Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept Completed NCT01901185 Phase 3 Etanercept / Autoinjector A
42 A Study of Ixekizumab in Participants With Active Psoriatic Arthritis Completed NCT01695239 Phase 3 Ixekizumab;Placebo;Adalimumab
43 Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis Completed NCT00317499 Phase 3 Etanercept
44 A Study of Golimumab in Participants With Active Psoriatic Arthritis Completed NCT02181673 Phase 3 Placebo;Golimumab
45 Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis Completed NCT01087788 Phase 3
46 A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) Completed NCT00427362 Phase 3 Adalimumab
47 A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis Completed NCT00265096 Phase 3
48 A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis Completed NCT00051623 Phase 3 Infliximab
49 A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents Completed NCT01077362 Phase 3 placebo;ustekinumab 45 mg;ustekinumab 90 mg
50 Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy Completed NCT00646178 Phase 3 adalimumab;placebo for adalimumab

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: arthritis, psoriatic

Sources

Genetic Tests for Psoriatic Arthritis

About this section

Genetic tests related to Psoriatic Arthritis:

# Genetic test Affiliating Genes
1 Psoriatic Arthritis, Susceptibility to 29 LTA NOD2
Sources

Anatomical Context for Psoriatic Arthritis

About this section

MalaCards organs/tissues related to Psoriatic Arthritis:

41
Skin, Testes, Bone, T Cells, Endothelial, Liver, Placenta
Sources

Publications for Psoriatic Arthritis

About this section

Articles related to Psoriatic Arthritis:

(show top 50) (show all 1142)
# Title Authors Year
1
"STATus of STAT3 in Psoriatic Arthritis." ( 29439293 )
2018
2
Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study. ( 29409133 )
2018
3
Effect of Biologics on Fatigue in Psoriatic Arthritis: A Systematic Literature Review with Meta-analysis. ( 29452303 )
2018
4
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. ( 29441473 )
2018
5
Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database. ( 29952704 )
2018
6
Enthesitis: A hallmark of psoriatic arthritis. ( 29429762 )
2018
7
Pain threshold and temporomandibular function in systemic sclerosis: comparison with psoriatic arthritis. ( 29445986 )
2018
8
Lipoma Arborescens Associated With Psoriatic Arthritis in an Adolescent Boy: A Case Report and Review of the Literature. ( 29933323 )
2018
9
Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study. ( 29862046 )
2018
10
Psoriatic arthritis screening by the dermatologist: development and first validation of the "PURE-4 scale". ( 29430720 )
2018
11
Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. ( 29417210 )
2018
12
Usefulness of dual-energy computed tomography for the evaluation of psoriatic arthritis accompanied by knee osteoarthritis. ( 29974970 )
2018
13
Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting. ( 29952225 )
2018
14
Early psoriatic arthritis in psoriatic patients: risk factors and screening for rheumatological evaluation. ( 29974947 )
2018
15
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naA^ve patients with active psoriatic arthritis (SPIRIT-P1). ( 29945203 )
2018
16
Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis. ( 29961685 )
2018
17
Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. ( 29929736 )
2018
18
Spondyloarthritis: Which composite measures to use in psoriatic arthritis? ( 29416138 )
2018
19
Cause-specific mortality in patients with psoriasis and psoriatic arthritis. ( 29947129 )
2018
20
Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study. ( 29980935 )
2018
21
'Deep Koebner' phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. ( 29511028 )
2018
22
Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. ( 29398124 )
2018
23
Correction:<i>Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force</i>. ( 29440019 )
2018
24
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). ( 29411182 )
2018
25
Early Psoriatic Arthritis Versus Early Seronegative Rheumatoid Arthritis: Role of Dermoscopy Combined with Ultrasonography for Differential Diagnosis. ( 29449498 )
2018
26
Current treatment options for psoriatic arthritis: spotlight on abatacept. ( 29922065 )
2018
27
Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis. ( 29449495 )
2018
28
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. ( 29667098 )
2018
29
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. ( 29425183 )
2018
30
Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. ( 29948352 )
2018
31
Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. ( 29394408 )
2018
32
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. ( 29927479 )
2018
33
Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. ( 29439292 )
2018
34
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. ( 29961691 )
2018
35
Underestimation of Risk of Carotid Subclinical Atherosclerosis by Cardiovascular Risk Scores in Patients with Psoriatic Arthritis: How Far Are We from the Truth? ( 29419446 )
2018
36
Hyperuricemia in Asian psoriatic arthritis patients. ( 29349920 )
2018
37
Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. ( 29907666 )
2018
38
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. ( 29928910 )
2018
39
Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study. ( 29975012 )
2018
40
Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review. ( 29949399 )
2018
41
A review of ustekinumab in the treatment of psoriatic arthritis. ( 29439608 )
2018
42
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. ( 29926091 )
2018
43
Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population. ( 29952710 )
2018
44
Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis. ( 28507491 )
2017
45
Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. ( 28855200 )
2017
46
Investigation of 36 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in a psoriatic arthritis cohort. ( 27988891 )
2017
47
[Psoriasis and Psoriatic Arthritis Induced by Nivolumab in a Patient with Advanced Non-Small-Cell Lung Cancer]. ( 28912410 )
2017
48
Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data. ( 29139035 )
2017
49
The LIM-Only Protein Four and a Half LIM Domain Protein 2 Attenuates Development of Psoriatic Arthritis by Blocking Adam17-Mediated Tumor Necrosis Factor Release. ( 28823868 )
2017
50
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. ( 28521047 )
2017
Sources

Variations for Psoriatic Arthritis

About this section

ClinVar genetic disease variations for Psoriatic Arthritis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TNF TNF, -308G-A single nucleotide variant risk factor
2 LTA NM_001159740.2(LTA): c.-9-198A> G single nucleotide variant risk factor rs909253 GRCh37 Chromosome 6, 31540313: 31540313
3 LTA NM_001159740.2(LTA): c.-9-198A> G single nucleotide variant risk factor rs909253 GRCh38 Chromosome 6, 31572536: 31572536
Sources

Expression for Psoriatic Arthritis

About this section
Search GEO for disease gene expression data for Psoriatic Arthritis.
Sources

Pathways for Psoriatic Arthritis

About this section

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.82 CD58 CRP HLA-B HLA-C IL13 IL1B
2
PAK Pathway 64
Show member pathways
 13.28 IL13 IL1B LTA PTPN22 TNF TNFRSF1A
3
Development Angiotensin activation of ERK 22
Show member pathways
 12.91 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
4
Cytokine Signaling in Immune system 66
Show member pathways
 12.84 HLA-B HLA-C IL13 IL1B LTA MMP3
5
Allograft rejection 1 37
Show member pathways
 12.8 HLA-B HLA-C IL13 IL1B LTA MICA
6
Apoptosis Modulation and Signaling 1
Show member pathways
 12.78 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B
7
Influenza A 37
Show member pathways
 12.77 HLA-B HLA-C IL13 IL1B LTA TNF
8
NF-KappaB Family Pathway 64
Show member pathways
 12.69 IL1B LTA TNF TNFRSF1A TNFRSF1B
9
4-1BB Pathway 64
Show member pathways
 12.65 IL1B LTA TNF TNFRSF1A TNFRSF1B
10
Regulation of IFNA signaling 66
Show member pathways
 12.64 HLA-B HLA-C IL13 IL1B LTA TNF
11
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.57 HLA-B HLA-C MICA TNF TNFRSF1A
12
NF-kappaB Signaling 4
12.52 IL1B PTPN22 TNF TNFRSF1A TNFRSF1B TNFSF11
13
HTLV-I infection 37
12.42 HLA-B HLA-C LTA TNF TNFRSF1A
14
Th17 cell differentiation 37
Show member pathways
 12.41 IL13 IL1B NOD2 TNF
15
TRAF Pathway 64
Show member pathways
 12.33 IL1B LTA TNF TNFRSF1A TNFRSF1B TNFSF11
16
IL-17 Family Signaling Pathways 65
Show member pathways
 12.32 IL13 IL1B MMP3 TNF
17
Apoptosis and Autophagy 4
12.23 TNF TNFRSF1A TNFRSF1B TNFSF11
18
Tuberculosis 37
12.22 IL1B NOD2 TNF TNFRSF1A
19
Cell adhesion molecules (CAMs) 37
12.11 CD58 HLA-B HLA-C SELE
20
Fluid shear stress and atherosclerosis 37
12.09 IL1B SELE TNF TNFRSF1A
21
Osteoclast differentiation 37
12.03 IL1B TNF TNFRSF11B TNFRSF1A TNFSF11
22
Interleukin-4 and 13 signaling 66
11.95 IL13 IL1B MMP3 TNF TNFRSF1B
23
AGE-RAGE signaling pathway in diabetic complications 37
11.86 IL1B SELE TNF
24
Rheumatoid arthritis 37
11.85 IL1B MMP3 TNF TNFSF11
25
NF-kappa B signaling pathway 37
11.85 IL1B LTA TNF TNFRSF1A TNFSF11
26
Innate Lymphoid Cell Differentiation Pathways 65
11.8 IL13 IL1B LTA TNF
27
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.75 TNF TNFRSF1A TNFRSF1B TNFSF11
28
Adipocytokine signaling pathway 37
11.69 TNF TNFRSF1A TNFRSF1B
29
Lung fibrosis 1
11.65 IL13 IL1B TNF
30
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.63 IL1B MMP3 SELE TNF TNFRSF1A
31
Transcription_NF-kB signaling pathway 22
11.61 LTA TNF TNFRSF1A TNFRSF1B
32
Cellular Transformation by HTLV1 64
Show member pathways
 11.56 LTA TNF TNFRSF1A TNFRSF1B
33
Malaria 37
11.54 COMP IL1B SELE TNF
34
Monoamine Transport 1
Show member pathways
 11.46 IL1B TNF TNFRSF11B
35
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.46 IL1B TNF TNFRSF11B TNFSF11
36
Interleukin-10 signaling 66
11.46 IL13 IL1B TNF TNFRSF1A TNFRSF1B
37
African trypanosomiasis 37
11.36 IL1B SELE TNF
38
14-3-3 and Regulation of BAD Activity 64
11.31 TNF TNFRSF1A TNFRSF1B
39
Development and heterogeneity of the ILC family 1
11.31 IL13 IL1B TNF
40
Cytokines and Inflammatory Response 1
11.28 IL13 IL1B TNF
41
TNF signaling pathway 37
11.26 IL1B LTA MMP3 NOD2 SELE TNF
42
Canonical NF-kappaB pathway 1
11.14 NOD2 TNF TNFRSF1A
43
TNFs bind their physiological receptors 66
11.03 LTA TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
44
Osteoblast Signaling 1
10.84 TNFRSF11B TNFSF11
Sources

GO Terms for Psoriatic Arthritis

About this section

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 CD58 HLA-B MICA SELE TNF TNFRSF11B
2 extracellular region GO:0005576 9.9 COMP CRP IL13 IL1B LTA MMP3
3 membrane raft GO:0045121 9.67 SELE TNF TNFRSF1A TNFRSF1B
4 cell surface GO:0009986 9.5 CD58 HLA-B HLA-C MICA NOD2 TNF
5 extracellular space GO:0005615 9.44 COMP CRP IL13 IL1B LTA MICA
6 MHC class I protein complex GO:0042612 9.32 HLA-B HLA-C

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.99 TNF TNFRSF11B TNFRSF1A TNFRSF1B
2 regulation of signaling receptor activity GO:0010469 9.99 IL13 IL1B LTA TNF TNFRSF11B TNFSF11
3 defense response to bacterium GO:0042742 9.98 MICA NOD2 TNF TNFRSF1A
4 leukocyte migration GO:0050900 9.96 CD58 IL1B SELE TNF
5 defense response GO:0006952 9.91 NOD2 TNF TNFRSF1A TNIP1
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 IL1B NOD2 TNF TNFSF11
7 cytokine-mediated signaling pathway GO:0019221 9.87 IL13 IL1B MMP3 TNF TNFRSF1A TNFRSF1B
8 cellular response to mechanical stimulus GO:0071260 9.86 IL13 IL1B TNFRSF1A
9 response to nutrient GO:0007584 9.86 LTA NOD2 TNFRSF11B
10 cellular response to organic cyclic compound GO:0071407 9.85 IL1B NOD2 TNF
11 positive regulation of MAP kinase activity GO:0043406 9.83 NOD2 TNF TNFSF11
12 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.81 TNF TNFRSF1A TNFRSF1B
13 positive regulation of interleukin-6 production GO:0032755 9.81 IL1B NOD2 TNF
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 IL1B NOD2 TNF
15 regulation of inflammatory response GO:0050727 9.8 NOD2 SELE TNF TNIP1
16 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.8 IL1B NOD2 TNF TNFRSF1A TNFSF11
17 positive regulation of interferon-gamma production GO:0032729 9.79 IL1B LTA TNF
18 apoptotic signaling pathway GO:0097190 9.78 TNF TNFRSF11B TNFRSF1A TNFRSF1B
19 positive regulation of JNK cascade GO:0046330 9.76 IL1B NOD2 TNF TNFSF11
20 response to lipopolysaccharide GO:0032496 9.76 IL13 IL1B LTA PTPN22 SELE TNFRSF11B
21 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.73 IL1B NOD2 TNF
22 tumor necrosis factor-mediated signaling pathway GO:0033209 9.73 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.72 IL1B PTPN22 TNF
24 positive regulation of interleukin-8 production GO:0032757 9.71 IL1B NOD2 TNF
25 negative regulation of growth of symbiont in host GO:0044130 9.69 LTA TNF
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 IL1B TNF
27 negative regulation of lipid storage GO:0010888 9.67 CRP TNF
28 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.67 HLA-B HLA-C
29 positive regulation of ceramide biosynthetic process GO:2000304 9.67 TNF TNFRSF1A
30 positive regulation of chemokine biosynthetic process GO:0045080 9.66 IL1B TNF
31 death-inducing signaling complex assembly GO:0071550 9.65 TNF TNFRSF1A
32 immune response GO:0006955 9.65 HLA-B HLA-C IL13 IL1B LTA TNF
33 positive regulation of fever generation GO:0031622 9.62 IL1B TNF
34 cellular response to muramyl dipeptide GO:0071225 9.62 NOD2 PTPN22
35 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IL1B TNF TNFRSF1B
36 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.6 LTA TNF
37 sequestering of triglyceride GO:0030730 9.59 IL1B TNF
38 positive regulation of protein K63-linked ubiquitination GO:1902523 9.58 NOD2 PTPN22
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.57 IL1B TNF
40 regulation of establishment of endothelial barrier GO:1903140 9.54 IL1B TNF TNFRSF1A
41 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.52 LTA TNF
42 inflammatory response GO:0006954 9.32 CRP IL13 IL1B NOD2 SELE TNF
43 apoptotic process GO:0006915 10.12 COMP IL1B LTA TNFRSF11B TNFRSF1A TNFRSF1B
44 positive regulation of gene expression GO:0010628 10.04 CRP IL1B MIR146A PTPN22 TNF

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 CD58 COMP CRP HLA-B HLA-C IL13
2 tumor necrosis factor receptor binding GO:0005164 9.43 LTA TNF TNFSF11
3 tumor necrosis factor-activated receptor activity GO:0005031 9.33 TNFRSF11B TNFRSF1A TNFRSF1B
4 cytokine activity GO:0005125 9.1 IL13 IL1B LTA TNF TNFRSF11B TNFSF11
Sources

Sources for Psoriatic Arthritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....